Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.
| Revenue (Most Recent Fiscal Year) | $36.75B |
| Net Income (Most Recent Fiscal Year) | $7.71B |
| PE Ratio (Current Year Earnings Estimate) | 16.70 |
| PE Ratio (Trailing 12 Months) | 17.09 |
| PEG Ratio (Long Term Growth Estimate) | 3.82 |
| Price to Sales Ratio (Trailing 12 Months) | 5.48 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 23.22 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 11.04 |
| Pre-Tax Margin (Trailing 12 Months) | 24.42% |
| Net Margin (Trailing 12 Months) | 20.98% |
| Return on Equity (Trailing 12 Months) | 148.37% |
| Return on Assets (Trailing 12 Months) | 13.23% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.14 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.90 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 5.78 |
| Inventory Turnover (Trailing 12 Months) | 1.86 |
| Book Value per Share (Most Recent Fiscal Quarter) | $16.06 |
| Earnings per Share (Most Recent Fiscal Quarter) | $5.29 |
| Earnings per Share (Most Recent Fiscal Year) | $21.84 |
| Diluted Earnings per Share (Trailing 12 Months) | $14.23 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Common Shares Outstanding | 539.07M |
| Free Float | 534.39M |
| Market Capitalization | $201.27B |
| Average Volume (Last 20 Days) | 2.98M |
| Beta (Past 60 Months) | 0.46 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.76% |
| Percentage Held By Institutions (Latest 13F Reports) | 76.50% |
| Annual Dividend (Based on Last Quarter) | $10.08 |
| Dividend Yield (Based on Last Quarter) | 2.70% |